Presented in concert with J.P. Morgan and Johnson & Johnson Innovation on May 18 and 19, the Conference brought together life sciences professionals from 9 countries and 20 states as well as the District of Columbia and featured nearly 70 company and pitch presentations, hundreds of 1:1 partnering meetings and plenary sessions led by industry leaders and world-renowned research institutions from the region.
Hepatitis B virus (HBV) infects at least 257 million individuals worldwide, often leading to liver disease and/or cancer. Current treatments for HBV are not curative. To address this need, Acurasset Therapeutics, a start-up spun out of the Ploss lab at Princeton University, is developing a novel approach to cure HBV based on small molecule therapeutics. Ploss and his group have established a short list of candidate molecules which inhibit factors necessary for HBV replication. If successful, this drug would rid cells of the virus within a matter of weeks to months, resulting in a single-treatment cure to HBV.
This article was originally published on the Department of Molecular Biology website.